[Sotrovimab in controlling SARS-CoV-2 infection]
- PMID: 35278299
[Sotrovimab in controlling SARS-CoV-2 infection]
Abstract
The new monoclonal antibodies - VIR -7831 (sotrovimab) and VIR- 7832 - show an action directly targeting the SARS-CoV-2 spike glycoprotein. Moreover, they strongly neutralize in vitro the wild-type Corona virus variants and the omicron variant. Sotrovimab is a monoclonal antibody capable of neutralizing SARS-CoV-2 as well as other sarbecoviruses (SARS-CoV-1 and SARS-CoV). The administration of 500 mg sotrovimab as a 1-hour intravenous infusion in 291 patients with COVID-19 with mild to moderate severity of symptoms prevented disease progression and the need for hospitalization.
Keywords: SARS-CoV-2; efficacy; sotrovimab.
© 2022 MEDPRESS.
Similar articles
-
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11. J Med Virol. 2022. PMID: 35662058 Free PMC article.
-
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate.Sci Rep. 2022 Mar 18;12(1):4683. doi: 10.1038/s41598-022-08559-5. Sci Rep. 2022. PMID: 35304531 Free PMC article.
-
Immune treatment in COVID-19.Rev Esp Quimioter. 2022 Apr;35 Suppl 1(Suppl 1):59-63. doi: 10.37201/req/s01.14.2022. Epub 2022 Apr 22. Rev Esp Quimioter. 2022. PMID: 35488829 Free PMC article. Review.
-
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.Int J Mol Sci. 2022 May 16;23(10):5556. doi: 10.3390/ijms23105556. Int J Mol Sci. 2022. PMID: 35628365 Free PMC article.
-
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.Viruses. 2024 Jan 31;16(2):217. doi: 10.3390/v16020217. Viruses. 2024. PMID: 38399991 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Miscellaneous